KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
https://pubmed.ncbi.nlm.nih.gov/38490803/Actively Recruiting
Led by Peking University First Hospital · Updated on 2025-09-08
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are investigating the use of new kidney-related biomarkers to predict acute kidney injury AKI and long-term chronic kidney disease CKD in patients undergoing radical nephrectomy, a surgery to remove a kidney. AKI occurs in over 40% of these patients, and current diagnostic methods relying on serum creatinine and urine output have limitations such as delayed response and inaccuracy. This study aims to evaluate how well these novel biomarkers can detect kidney injury early and predict kidney disease up to one year after surgery. Participants scheduled for unilateral radical nephrectomy will be monitored for specific urinary and blood biomarkers, including TIMP-2IGFBP-7, NGAL, KIM-1, and serum cystatin C. The study groups include patients who develop AKI or newworsening CKD after surgery and those who do not. Biomarker levels will be assessed within 7 days post-surgery to predict AKI and up to one year to evaluate CKD outcomes. Researchers will also examine combinations of biomarkers and clinical risk factors to improve prediction accuracy. During the study, participants will undergo biomarker testing at specified times after surgery, with follow-up assessments extending up to one year. Researchers will review urinary and blood samples to measure kidney function changes and correlate biomarker levels with kidney injury outcomes. The main focus is on how well these biomarkers predict AKI within the first week and CKD within one year after nephrectomy, helping to identify patients at risk and guide future care approaches.
CONDITIONS
Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy
Q
Qiongfang Wu, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Peking University First Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 7 days after surgery
Participants undergo radical nephrectomy and immediate post-operative assessments for kidney function and biomarkers.
Daily visits or assessments during hospital stay up to 7 days
Duration - Up to 1 year after surgery
Participants are monitored for the new onset or worsening of chronic kidney disease after surgery.
Periodic visits over 1 year for kidney function assessment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
https://pubmed.ncbi.nlm.nih.gov/38490803/Adam Rossiter, Ashley La, Jay L Koyner...
https://pubmed.ncbi.nlm.nih.gov/37668397/Ah Young Leem, Moo Suk Park, Byung Hoon Park...
https://pubmed.ncbi.nlm.nih.gov/28332367/Arif Khwaja
https://pubmed.ncbi.nlm.nih.gov/22890468/Ivan Göcze, Dominik Jauch, Markus Götz...
https://pubmed.ncbi.nlm.nih.gov/28857811/Marlies Ostermann, Alexander Zarbock, Stuart Goldstein...
https://pubmed.ncbi.nlm.nih.gov/33021646/Sandra L Kane-Gill, Sadudee Peerapornratana, Adrian Wong...
https://pubmed.ncbi.nlm.nih.gov/32086072/Alessandro Antonelli, Marco Allinovi, Andrea Cocci...
https://pubmed.ncbi.nlm.nih.gov/30309817/Peking University First Hospital
Lead Sponsor